With Purdue Pharma plotting a future beyond the bankruptcy proceedings now consuming the company, its drug development subsidiary Imbrium Therapeutics has secured global rights to a drug candidate that could play a role in the move beyond opioids.

Imbrium has bought a non-opioid treatment for interstitial cystitis/bladder pain syndrome (IC/BPS) from PureTech Health.

Canadian Aquinox Pharmaceuticals' once-daily, oral rosiptor (AQX-1125) failed to meet the primary endpoint of the Phase 3 LEADERSHIP 301 trial in interstitial cystitis/bladder pain syndrome (IC/BPS), leaving the company's stock value in tatters.

Just weeks after Astellas agreed to pay Aquinox Pharmaceuticals $25 million upfront for Asian rights to their lead drug rosiptor, the little biotech says their Phase III trial was a complete disaster, leaving nothing to salvage.